Form D · Biotechnology

Bioniz Therapeutics, Inc.

Irvine, CA · CIK 0001662388

Offering snapshot reported Jan 24, 2019 · SEC filing

Reported sold
$8M
Offering amount: $8M
Investors reported
9
Form D · investor count
Minimum accepted
$0
Reported outside-investor minimum
First sale
Jan 18, 2019
As reported in this filing

What changed?

Latest filing versus its linked predecessor, where available.

No comparable changes in the displayed metrics.

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
Jan 24, 2019Initial$8,000,000No comparison9SEC filing
Apr 13, 2017Amendment$15,551,250$4,776,254vs Aug 17, 201614SEC filing
Apr 13, 2017Amendment$15,551,250$0vs Apr 13, 201715SEC filing
Aug 17, 2016Amendment$10,774,996$7,209,996vs Dec 30, 201512SEC filing
Apr 22, 2016Amendment$5,674,998$2,109,998vs Dec 30, 20159SEC filing
Dec 30, 2015Initial$3,565,000No comparison5SEC filing

Offering details

Securities
Debt
Exemptions
06b
Duration over one year
No
Business combination
No
Sales commissions
$0
Finders' fees
$0
Form D file number
021-331334

Source: Form D, filed Jan 24, 2019. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
Nazli Azimi Director, Executive
Graham Cooper Director
Paul Frohna Executive
Joe Kiani Director
Michael Martin Director
David E.I. Pyott Director
Fredrik Wiklund Executive
Kleanthis Xanthopoulos Director
Ilan Zipkin Director

Issuer details

Industry: Biotechnology (See others in industry)

Address:
5 Mason Suite 275
Irvine, CA, 92618